IP Library Granted Patent US 9,883,907
Granted Patent B2
US 9,883,907 · App. 13/488,214 · Granted Feb 6, 2018

Methods for evaluating the integrity of a uterine cavity

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,883,907
App. No.
13/488,214
Granted
Feb 6, 2018
Kind
B2
Abstract

Methods, systems and devices for evaluating the integrity of a uterine cavity. A method comprises introducing transcervically a probe into a patient's uterine cavity, providing a flow of a fluid (e.g., CO 2 ) through the probe into the uterine cavity and monitoring the rate of the flow to characterize the uterine cavity as perforated or non-perforated based on a change in the flow rate.

Claims (27)

1. A method for treatment of uterine tissue, comprising:

positioning an expandable structure in a patient's uterine cavity, the expandable structure comprising a portion of an energy application system for delivering ablation energy to uterine tissue;

expanding the expandable structure to occupy a substantial volume of the patient's uterine cavity;

introducing a gas into the uterine cavity exterior of the expandable structure;

introducing a gas into the expandable structure as the expandable structure expands;

monitoring a parameter of the gas introduced into the expandable structure as the expandable structure expands to determine whether the uterine cavity is perforated or non-perforated; and

monitoring a parameter of the gas introduced into the uterine cavity exterior of the expandable structure as the expandable structure expands to determine whether the uterine cavity is perforated or non-perforated,

wherein the parameter of the gas introduced into the uterine cavity is gas volume, and

wherein the monitoring of the parameter of the gas introduced into the uterine cavity exterior of the expandable structure as the expandable structure expands to determine whether the uterine cavity is perforated or non-perforated comprises determining that the uterine cavity is perforated if the gas volume is less than a first threshold volume after a predetermined period of time.

2. The method of claim 1 , wherein the positioning step comprises transcervically introducing an elongated member into the uterine cavity, the elongated member carrying the expandable structure.

3. The method of claim 1 , wherein the positioning step includes expanding the expandable structure with at least one of a frame and gas pressure.

4. The method of claim 1 wherein an additional monitored parameter of the gas introduced into the expandable structure or the uterine cavity is a gas flow rate or change in gas flow rate.

5. The method of claim 4 , wherein the uterine cavity is determined as perforated if the gas flow rate into the expandable structure or the uterine cavity meets a predetermined decay.

6. The method of claim 5 , wherein the gas flow rate into the expandable structure or the uterine cavity meets a predetermined decay if the gas flow rate drops below a predetermined minimum threshold rate within the predetermined period of time.

7. The method of claim 1 wherein an additional monitored parameter of the gas introduced into the expandable structure or the uterine cavity is gas pressure.

8. The method of claim 7 , wherein the uterine cavity is determined as perforated if the gas pressure in the expandable structure and the gas pressure in the uterine cavity reach an equilibrium.

9. The method of claim 1 wherein the parameter of the gas introduced into the expandable structure is gas volume.

10. The method of claim 9 , further comprising determining that the uterine cavity is perforated if the gas volume of the gas introduced into the expandable structure is less than a second threshold volume.

11. The method of claim 1 wherein the parameter of the gas introduced into the expandable structure and the parameter of the gas introduced into the uterine cavity are monitored contemporaneously.

12. The method of claim 1 wherein the parameter of the gas introduced into the expandable structure and the parameter of the gas introduced into the uterine cavity are monitored sequentially.

13. The method of claim 1 wherein the parameter of the gas introduced into the uterine cavity is monitored first and then the parameter of the gas introduced into the expandable structure is monitored.

14. The method of claim 1 wherein the parameter of the gas introduced into the expandable structure is monitored first and then the parameter of the gas introduced into the uterine cavity is monitored.

15. The method of claim 1 wherein monitoring the parameter of the gas introduced into the uterine cavity exterior of the expandable structure includes monitoring the parameter of the gas introduced into the uterine cavity at least twice.

16. The method of claim 1 wherein monitoring the parameter of the gas introduced into the expandable structure includes monitoring the parameter of the gas introduced into the expandable structure at least twice.

17. The method of claim 1 further comprising delivering the ablation energy to the uterine tissue when the monitoring step of monitoring the parameter of the gas introduced into the uterine cavity exterior of the expandable structure indicates that the uterine cavity is non-perforated.

18. The method of claim 1 further comprising automatically activating the energy application system to deliver ablation energy to the uterine tissue when both of the monitoring steps determine that the uterine cavity is non-perforated.

19. The method of claim 1 , wherein the predetermined period of time is in the range from 1 second to 60 seconds.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2026
From: MINERVA SURGICAL, INC.
To: AXORA MEDICAL, INC.
Reel/Frame 075561/0186 →
RELEASE OF SECURITY INTEREST Recorded Feb 5, 2026
From: CANADIAN IMPERIAL BANK OF COMMERCE
To: MINERVA SURGICAL, INC.
Reel/Frame 074721/0585 →
SECURITY INTEREST Recorded Jan 30, 2026
From: AXORA MEDICAL, INC.
To: SYMBIOTIC CAPITAL AGENCY LLC, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
Reel/Frame 074537/0617 →
RELEASE OF SECURITY INTEREST Recorded Oct 12, 2021
From: ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
To: MINERVA SURGICAL, INC.
Reel/Frame 057770/0451 →
SECURITY INTEREST Recorded Oct 8, 2021
From: MINERVA SURGICAL, INC.
To: CANADIAN IMPERIAL BANK OF COMMERCE
Reel/Frame 057758/0137 →
SECURITY INTEREST Recorded Dec 31, 2019
From: MINERVA SURGICAL, INC.
To: ARES CAPITAL CORPORATION
Reel/Frame 051395/0275 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2017
From: TOTH, AKOS; BEK, ROBIN; FILLOUX, DOMINIQUE; MAZMUDAR, TEJAS N.; TRUCKAI, CSABA
To: MINERVA SURGICAL, INC.
Reel/Frame 043864/0728 →